• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Faraday Future Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

    11/24/23 7:59:45 AM ET
    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Medical/Dental Instruments
    Health Care
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $AEMD alert in real time by email

    Shares of Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) surged in pre-market trading after the company announced its foray into the Middle East market.

    Faraday Future revealed in press release that the company will release the FF 91 2.0 Futurist aiFalcon, with deliveries starting in 2024.

    Faraday Future shares rose 14.1% to $0.5590 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • FLJ Group Limited (NASDAQ:FLJ) shares rose 126.7% to $0.2451 in pre-market trading. FLJ Group signed a definitive deal to acquire Alpha Mind Technology Limited.
    • Telesis Bio, Inc. (NASDAQ:TBIO) shares rose 37.1% to $0.5482 in pre-market trading after surging 33% on Wednesday.
    • iRobot Corporation (NASDAQ:IRBT) rose 34.1% to $39.98 in pre-market trading. Amazon.com Inc.’s (NASDAQ:AMZN) proposed acquisition of iRobot is reportedly on the verge of receiving unconditional approval from European Union antitrust authorities.
    • BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares surged 30.6% to $0.4819 in pre-market trading after falling 3% on Wednesday.
    • Bruush Oral Care Inc.(NASDAQ:BRSH) gained 29.6% to $0.3305 in pre-market trading after falling around 15% on Wednesday. On Nov. 15, Brush Oral Care received a notice from the Nasdaq Listing Qualifications Department that the company is currently not in compliance with the minimum bid price requirement because the closing bid price of BRSH shares was below $1.00 per share for a period of 30 consecutive business days.
    • MMTec, Inc. (NASDAQ:MTC) shares climbed 21.3% to $1.19 in pre-market trading. The company recently reported a narrower loss for H1.
    • VBI Vaccines Inc. (NASDAQ:VBIV) rose 16.2% to $0.6389 in pre-market trading after falling around 21% on Wednesday. VBI Vaccines recently posted downbeat quarterly results.
    • Iveda Solutions, Inc. (NASDAQ:IVDA) shares rose 12.7% to $0.71 in pre-market trading after gaining more than 10% on Wednesday.
    • UpHealth, Inc. (NYSE:UPH) gained 11.5% to $0.68 in pre-market trading after declining 23% on Wednesday.

    Losers

    • Impel Pharmaceuticals Inc. (NASDAQ:IMPL) dipped 28.2% to $0.5597 in pre-market trading after jumping 143% on Wednesday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.
    • Aethlon Medical, Inc. (NASDAQ:AEMD) shares fell 17.2% to $1.40 in pre-market trading. The company recently posted a narrower-than-expected quarterly loss.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) shares fell 15.4% to $0.61 in pre-market trading after declining around 7% on Wednesday.
    • Reliance Global Group, Inc. (NASDAQ:RELI) fell 13.1% to $1.13 in pre-market after jumping 53% on Wednesday. Reliance Global recently announced it withdrew its proposed underwritten public offering and also announced it has entered into a Letter of Intent to acquire a benefits enrollment company.
    • Ikena Oncology, Inc. (NASDAQ:IKNA) fell 12.3% to $1.43 in pre-market trading. Ikena Oncology recently reported worse-than-expected third-quarter revenue results.
    • Seelos Therapeutics, Inc. (NASDAQ:SEEL) fell 11.8% to $0.1498 in pre-market trading after jumping over 30% on Wednesday.
    • BuzzFeed, Inc. (NASDAQ:BZFD) shares fell 9.6% to $0.2805 in pre-market trading. The company recently posted downbeat quarterly results.
    • Heart Test Laboratories, Inc. (NASDAQ:HSCS) fell 9.5% to $0.2137 in pre-market trading after jumping 20% on Wednesday.
    • Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) shares fell 9.1% to $1.99 in pre-market trading. Cardio Diagnostics recently announced the publication of a study on the development and validation of PrecisionCHD in the Journal of the American Heart Association.
    • Cuentas Inc. (NASDAQ:CUEN) shares fell 8.7% to $1.26 in pre-market trading after declining 11% on Wednesday. Cuentas recently posted a narrower quarterly loss.

     

    Now Read This: Walmart, Best Buy And 3 Stocks To Watch Heading Into Friday

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $AMZN
    $BGLC
    $BRSH

    CompanyDatePrice TargetRatingAnalyst
    Amazon.com Inc.
    $AMZN
    2/23/2026$305.00 → $304.00Overweight
    Wells Fargo
    Amazon.com Inc.
    $AMZN
    2/6/2026$300.00 → $280.00Buy
    Monness Crespi & Hardt
    Amazon.com Inc.
    $AMZN
    2/6/2026$175.00Buy → Neutral
    DA Davidson
    Amazon.com Inc.
    $AMZN
    2/2/2026$300.00 → $315.00Mkt Outperform
    Citizens JMP
    Amazon.com Inc.
    $AMZN
    1/28/2026$305.00 → $315.00Outperform
    Oppenheimer
    Amazon.com Inc.
    $AMZN
    1/28/2026$303.00 → $308.00Overweight
    KeyBanc Capital Markets
    Amazon.com Inc.
    $AMZN
    1/27/2026$295.00 → $300.00Buy
    Stifel
    Amazon.com Inc.
    $AMZN
    1/27/2026$303.00 → $286.00Buy
    BofA Securities
    More analyst ratings

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Worldwide Amazon Stores Herrington Douglas J converted options into 11,959 shares and sold $948,990 worth of shares (4,784 units at $198.37), increasing direct ownership by 1% to 512,109 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 6:16:06 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Gorelick Jamie S converted options into 2,677 shares, increasing direct ownership by 7% to 40,794 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 6:05:51 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Director Weeks Wendell P converted options into 1,816 shares, increasing direct ownership by 4% to 46,216 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    2/18/26 5:57:32 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo reiterated coverage on Amazon with a new price target

    Wells Fargo reiterated coverage of Amazon with a rating of Overweight and set a new price target of $304.00 from $305.00 previously

    2/23/26 10:45:11 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Monness Crespi & Hardt reiterated coverage on Amazon with a new price target

    Monness Crespi & Hardt reiterated coverage of Amazon with a rating of Buy and set a new price target of $280.00 from $300.00 previously

    2/6/26 8:23:18 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon downgraded by DA Davidson with a new price target

    DA Davidson downgraded Amazon from Buy to Neutral and set a new price target of $175.00

    2/6/26 8:06:19 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    SEC Filings

    View All

    Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/23/26 4:15:32 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioNexus Gene Lab Corp (0001737523) (Filer)

    2/23/26 8:35:38 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)

    2/19/26 8:00:30 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P converted options into 379 shares and bought $2,499,969 worth of shares (83,611 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:51:45 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Stampacchia Otello converted options into 379 shares and bought $7,999,924 worth of shares (267,556 units at $29.90) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    7/30/25 4:47:09 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Global Chief Executive Officer Aydt Matthias bought $100 worth of Series A Preferred Stock (1 units at $100.00) (SEC Form 4)

    4 - FARADAY FUTURE INTELLIGENT ELECTRIC INC. (0001805521) (Issuer)

    1/30/25 9:36:52 PM ET
    $FFIE
    Auto Manufacturing
    Consumer Discretionary

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Leadership Updates

    Live Leadership Updates

    View All

    BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

    Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), today announced the completion of a governance restructuring of its wholly owned subsidiary, Chemrex Corporation Sdn. Bhd. ("Chemrex"). As part of this restructuring, Chemrex's board has been streamlined to two directors: Matthew L. Barsing, ChairmanAngeline Chong, Chief Financial Officer of BioNexus, Director New officers are expected to be appointed in the coming months. Chemrex remains a wholly owned private subsidiary of BioNexus and operates un

    2/23/26 8:30:00 AM ET
    $BGLC
    Medical Specialities
    Health Care

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Circana Appoints Highly Regarded Business Leaders to Board of Directors

    Chicago, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Circana LLC, a leading global provider of data, insights, and advisory services, today announced the appointment of three new members to its Board of Directors: Brian Cornell, Executive Chair of Target Corp.; Lauren Cooks Levitan, Co-Founder and Co-CEO of ROOT and Lead Independent Director at e.l.f. Beauty, Inc.; and Rohit Prasad, former Senior Vice President and Head Scientist of Artificial General Intelligence at Amazon.com, Inc. "These appointments strengthen the Board's ability to guide Circana's strategy and accelerate the value we deliver to our global clients," said Stuart Aitken, President and CEO of Circana. "We are focused on advancing

    2/11/26 8:00:00 AM ET
    $AMZN
    $TGT
    Catalog/Specialty Distribution
    Consumer Discretionary
    Department/Specialty Retail Stores

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Financials

    Live finance-specific insights

    View All

    Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026

    Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) ("Cardio Diagnostics" or the "Company"), a precision cardiovascular medicine company leveraging epigenetics, genetics, and artificial intelligence for the prevention and detection of cardiovascular disease, today announced that it will host an investor conference call on Wednesday, February 18, 2026, at 3 p.m. Central Time. The call will provide an overview of the Company's precision molecular approach to cardiovascular disease prevention and early detection, including updates on its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™, recent breakthrough clinical data, reimbursement progress, and strategic growth initiatives. Web

    2/17/26 8:35:00 AM ET
    $CDIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Amazon.com Announces Fourth Quarter Results

    Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its fourth quarter ended December 31, 2025. Fourth Quarter 2025 Net sales increased 14% to $213.4 billion in the fourth quarter, compared with $187.8 billion in fourth quarter 2024. Excluding the $2.8 billion favorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 12% compared with fourth quarter 2024. North America segment sales increased 10% year-over-year to $127.1 billion. International segment sales increased 17% year-over-year to $50.7 billion, or increased 11% excluding changes in foreign exchange rates. AWS segment sales increased 24% year-over

    2/5/26 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AEMD
    $AMZN
    $BGLC
    $BRSH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    11/14/24 7:32:44 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ikena Oncology Inc.

    SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

    11/14/24 5:05:17 PM ET
    $IKNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care